Christopher Linskey, MD
Psychiatry · Page, AZNPI 1790775757
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $100,286 of the $100,329 with a category attached, or 100.0%. Kedplasma LLC accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. 2023 is the largest year on record at $59,002, more than ten times the $19 reported in 2019. Among psychiatry clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $1967.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kedplasma LLC$100K
- Johnson & Johnson$43
What the payments were for
- Consulting fees$100,286100%
- Food & beverage$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kedplasma LLC | 49 | $100,286 |
| Johnson & Johnson | 2 | $43 |
How this compares
$100,329 in reported general payments places this provider in the 95th percentile of 573 psychiatry providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 11 | $40,697 |
| RisperdalRisperidone | 11 | $4,880 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,431 |
| Quetiapine Fumarate | 159 | $3,168 |
| Duloxetine Hcl | 97 | $2,029 |
| Clozapine | 11 | $2,017 |
| Divalproex Sodium ErDivalproex Sodium | 24 | $1,796 |
| Tranylcypromine Sulfate | 12 | $1,560 |
| Fluoxetine Hcl | 56 | $1,492 |
| Risperidone | 98 | $1,395 |
| Trazodone Hcl | 123 | $1,141 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 21 | $1,045 |
| Clonazepam | 134 | $930 |
| AmantadineAmantadine Hcl | 17 | $918 |
| Mirtazapine | 51 | $838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal | $43 | $45,57722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Page
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Monica BenavidezPhoenix$435K
- Bahar GolestanMesa$234K
- Eric ReimanPhoenix$157K
- Henry SchulteScottsdale$77K
- Marlene FreemanTucson$59K
- Lauren BonnerScottsdale$44K
- Padma AkingPhoenix$44K
- Francisco MorenoTucson$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.